• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

镰状细胞病中的组织型纤溶酶原激活物抗原与活性

Tissue type plasminogen activator antigen and activity in sickle cell disease.

作者信息

Francis R B

机构信息

Department of Medicine, Los Angeles County University of Southern California Medical Center.

出版信息

J Clin Pathol. 1988 May;41(5):490-3. doi: 10.1136/jcp.41.5.490.

DOI:10.1136/jcp.41.5.490
PMID:3133398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1141498/
Abstract

To investigate the hypothesis that diminished endothelial fibrinolysis is present in sickle cell (SS) disease plasma, tissue type plasminogen activator (t-PA) antigen titres were measured before and after a standard stimulus of endothelial t-PA release (venous occlusion of the arm), and plasma t-PA activities after venous occlusion in 33 subjects with SS disease and in 32 healthy subjects. Mean plasma t-PA antigen titres before and after venous occlusion, and mean plasma t-PA activities after venous occlusion did not differ significantly between SS patients and normal subjects. No significant differences in mean t-PA antigen and activity were observed between samples taken from inpatients being treated for acute pain crisis (18 subjects, 30 samples) and samples taken from subjects in the steady state (23 subjects, 26 samples). No consistent differences were seen between painful crisis and steady state samples in eight SS patients studied while in crisis and in the steady state. No correlation was observed between any fibrinolytic variable in SS patients and the overall severity of microvascular occlusive disease as measured by a standard scoring system. It is concluded that the capacity of endothelium to synthesise and release t-PA is not impaired in SS disease, and that excessive inhibition of released t-PA, leading to reduced t-PA activity in plasma is also not a feature of SS disease, either in the steady state or during painful crisis.

摘要

为了研究镰状细胞(SS)病血浆中存在内皮纤溶功能减退这一假说,我们测定了33例SS病患者和32例健康受试者在标准刺激内皮组织型纤溶酶原激活物(t-PA)释放(手臂静脉阻塞)前后的t-PA抗原滴度,以及静脉阻塞后的血浆t-PA活性。SS病患者和正常受试者在静脉阻塞前后的平均血浆t-PA抗原滴度以及静脉阻塞后的平均血浆t-PA活性并无显著差异。在接受急性疼痛危象治疗的住院患者(18例受试者,30份样本)和处于稳定状态的受试者(23例受试者,26份样本)所采集的样本之间,未观察到平均t-PA抗原和活性的显著差异。在对8例处于疼痛危象期和稳定期的SS病患者进行研究时,疼痛危象期和稳定期的样本之间未发现一致的差异。通过标准评分系统测定,SS病患者的任何纤溶变量与微血管闭塞性疾病的总体严重程度之间均未观察到相关性。得出的结论是,SS病患者内皮合成和释放t-PA的能力并未受损,而且在稳定状态或疼痛危象期间,血浆中t-PA活性降低的原因也并非是释放的t-PA受到过度抑制。

相似文献

1
Tissue type plasminogen activator antigen and activity in sickle cell disease.镰状细胞病中的组织型纤溶酶原激活物抗原与活性
J Clin Pathol. 1988 May;41(5):490-3. doi: 10.1136/jcp.41.5.490.
2
Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.使用单克隆抗组织型纤溶酶原激活剂抗体的组织型纤溶酶原激活剂抗原和功能联合检测系统评估纤溶能力。
J Lab Clin Med. 1987 Jun;109(6):665-71.
3
Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.健康受试者对静脉闭塞的纤溶反应的可重复性。
Thromb Haemost. 1995 Mar;73(3):453-7.
4
Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.青少年血液纤溶成分的年龄依赖性以及低剂量口服避孕药对青少年凝血和纤溶的影响。
Thromb Haemost. 1988 Dec 22;60(3):361-4.
5
Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
Thromb Haemost. 1988 Jun 16;59(3):412-4.
6
Regulation of tissue plasminogen activator in sickle cell anemia.镰状细胞贫血中组织型纤溶酶原激活物的调节
Am J Hematol. 1990 Nov;35(3):167-70. doi: 10.1002/ajh.2830350305.
7
Tissue plasminogen activator release in chronic venous hypertension due to heart failure.心力衰竭所致慢性静脉高压时组织型纤溶酶原激活物的释放
Thromb Haemost. 1992 Sep 7;68(3):321-4.
8
Hypofibrinolysis in patients with a history of idiopathic deep vein thrombosis and/or pulmonary embolism.有特发性深静脉血栓形成和/或肺栓塞病史患者的纤溶功能减退。
Thromb Haemost. 1992 Apr 2;67(4):397-401.
9
Fibrinolytic response to venous occlusion for 10 and 20 minutes in healthy subjects and in patients with deep vein thrombosis.健康受试者和深静脉血栓形成患者对静脉阻塞10分钟和20分钟的纤溶反应。
Thromb Res. 1989 Oct 15;56(2):251-63. doi: 10.1016/0049-3848(89)90167-9.
10
Fibrinolysis in normal subjects--comparison between plasminogen activator inhibitor and other components of the fibrinolytic system.正常受试者的纤维蛋白溶解——纤溶酶原激活物抑制剂与纤维蛋白溶解系统其他成分的比较
Thromb Haemost. 1988 Apr 8;59(2):299-303.

本文引用的文献

1
Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity.镰状细胞贫血中红细胞与内皮细胞的黏附。疾病严重程度的一个可能决定因素。
N Engl J Med. 1980 May 1;302(18):992-5. doi: 10.1056/NEJM198005013021803.
2
Sickled erythrocytes accelerate clotting in vitro: an effect of abnormal membrane lipid asymmetry.镰状红细胞在体外会加速凝血:这是异常膜脂不对称性的一种效应。
Blood. 1981 Aug;58(2):398-401.
3
Abnormalities in membrane phospholipid organization in sickled erythrocytes.镰状红细胞膜磷脂组织异常。
J Clin Invest. 1981 Jun;67(6):1643-9. doi: 10.1172/jci110200.
4
Aspirin-dipyridamole prophylaxis of sickle cell disease pain crises.阿司匹林-双嘧达莫预防镰状细胞病疼痛危象
Thromb Haemost. 1980 Jul 15;43(3):218-21.
5
Impaired fibrinolytic capacity predisposes for recurrence of venous thrombosis.
Thromb Haemost. 1984 Oct 31;52(2):127-30.
6
Fibrinolytic activity in the clinical crisis of sickle-cell anaemia.镰状细胞贫血临床危象中的纤溶活性。
Br Med J. 1967 Sep 9;3(5566):653-4. doi: 10.1136/bmj.3.5566.653.
7
Platelet function and survival in sickle cell disease.镰状细胞病中的血小板功能与存活情况
J Lab Clin Med. 1973 Jul;82(1):44-53.
8
Coagulation fibrinolysis in sickle-cell disease.镰状细胞病中的凝血与纤维蛋白溶解
J Clin Pathol. 1974 Jun;27(6):485-9. doi: 10.1136/jcp.27.6.485.
9
Haemostatic function in myocardial infarction.心肌梗死中的止血功能。
Br Heart J. 1986 Jan;55(1):58-66. doi: 10.1136/hrt.55.1.58.
10
The role of the fibrinolytic system in deep vein thrombosis.纤维蛋白溶解系统在深静脉血栓形成中的作用。
J Lab Clin Med. 1985 Feb;105(2):265-70.